Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
Список исп. литературыСкрыть список 1. Cannell JJ, Vieth R, Umhau JC et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134: 1129–40. 2. Heaney RP. Vitamin D-baseline status and effective dose. N Engl J Med 2008; 367: 77–8. 3. Ingham TR, Jones B, Camargo CA et al. Association of vitamin D deficiency with severity of acute respiratory infection: A case-control study in New Zealand children. Eur Respir J 2014; 44: 439. 4. Bouillon R, Carmeliet G, Verlinden L et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726–76. 5. Wang C, Horby PW, Hayden FG et al. A novel coronavirus outbreak of global health concern. Lancet 2020; 395: 470–3. 6. Song Z, Xu Y, Bao L et al. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses 2019; 11: 59. 7. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266–81. 8. Hewison M, Gacad MA, Lemire J et al. Vitamin D as a cytokine and hematopoetic factor. Rev Endocr Metab Disord 2001; 2: 217–27. 9. Wacker M, Holick MF. Vitamin D – Effects on skeletal and extraskeletal health and the need for supplementation. Nutrients 2013; 5: 111–48. 10. Wang TJ, Zhang F, Richards JB et al. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet 2010; 376: 180–8. 11. Ross AC, Manson JE, Abrams SA et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. JCEM 2011; 96: 53–8. 12. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol 2012; 76: 315–25. 13. Chen G, Wu D, Guo W et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130 (5): 2620–9. 14. Pan Y, Zhang D, Yang P et al. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 2020; 20: 411–2. 15. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770–3. 16. Zou L, Ruan F, Huang M et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med 2020; 382: 1177–9. 17. White JH. Vitamin D metabolism and signaling in the immune system. Rev Endocr Metab Disord 2012; 13: 21–9. 18. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–13. 19. Edfeldt K, Liu PT, Chun R et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci USA 2010; 107: 22593–8. 20. Jeng L, Yamshchikov AV, Judd SE et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 2009; 7: 28. 21. Gorbalenya AE, Snijder EJ, Ziebuhr J. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol 2000; 81: 853–79. 22. Báez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral Res 2015; 115: 21–38. 23. Müller K, Diamant M, Bendtzen K. Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. Immunol Lett 1991; 28: 115–20. 24. Rigby WF, Waugh MG. Decreased accessory cell function and costimulatory activity by 1,25-dihydroxyvitamin D3-treated monocytes. Arthritis Rheum 1992; 35: 110–19. 25. Deming D, Sheahan T, Heise M et al. Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants. PLoS Med 2006; 3: e525. 26. Yasui F, Kai C, Kitabatake M et al. Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV. J Immunol 2008; 181: 6337–48. 27. Li XY, Du B, Wang YS et al. The keypoints in treatment of the critical coronavirus disease 2019 patient(2). Chin J Tuberc Respir Dis 2020; 43: 277–81. 28. Sheahan TP, Sims AC, Graham RL et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9 (396): eaal3653. 29. Chu C, Cheng V, Hung I et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252–6. 30. Savarino A, Boelaert JR, Cassone A et al. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis 2003; 3: 722–7. 31. Lemire JM, Adams JS, Kermani-Arab V et al. 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 1985; 134: 3032–5. 32. Cantorna MT. Mechanisms underlying the effect of vitamin D on the immune system. Proc Nutr Soc 2011; 69: 286–9. 33. Lemire JM, Adams JS, Sakai R et al. 1alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Investig 1984; 74 (2): 657–61. 34. Pilz S, Zittermann A, Trummer C et al. Vitamin D testing and treatment: a narrative review of current evidence. Endocr Connect 2019; 8 (2): R27–R43. 35. Bouillon R, Marcocci C, Carmeliet G et al. Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. Endocr Rev 2019; 40: 1109–51. 36. Hamming I, Cooper ME, Haagmans BL et al. The emerging role of ACE2 in physiology and disease. J Pathol 2007; 212 (1): 1–11. 37. Zhou P, Yang X, Lou Wang XG et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270–3. 38. Lambert DW, Yarski M, Warner FJ et al. Tumor necrosis factor-alpha convertase (AD-AM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 2005; 280 (34): 30113–9. 39. Zhang H, Penninger JM, Li Y et al Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46: 586–90. 40. Mill_an-O~nate J, Rodriguez-Morales AJ, Camacho-Moreno G et al. A new emerging zoonotic virus of concern: the 2019 novel Coronavirus (COVID-19). Infect 2020; 24: 187. 41. Marshall RP, Webb S, Bellingan GJ et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 166: 646–50. 42. Imai Y, Kuba K, Rao S et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436: 112–6. 43. Kuba K, Imai Y, Rao S et al. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. J Mol Med 2006; 84: 814–20. 44. Venkatram S, Chilimuri S, Adrish M et al. Vitamin D deficiency is associated with mortality in the medical intensive care unit. Crit Care 2011; 15: R292. 45. Xu J, Yang J, Chen J et al. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol Med Rep 2017; 16: 7432–8. 46. Ishii K, Takeuchi H, Fukunaga K et al. Attenuation of lipopolysaccharide-induced acute lung injury after (pro)renin receptor blockade. Exp Lung Res 2015; 41: 199–207. 47. Li YC, Qiao G, Uskokovic M et al. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89–90 (1–5): 387–92.